-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Globally, there will be approximately 573,000 bladder cancer patients and 212,000 deaths in 2020
In order to identify patients with increased likelihood of residual disease after surgery, a blood test is used to detect the presence of circulating tumor genes (ctDNA)
CtDNA from solid tumors is released into the blood
CtDNA from solid tumors is released into the bloodAccording to a clinical study conducted by Queen Mary University of London, blood tests related to ctDNA may be able to identify the risk of cancer recurrence and guide the precise treatment of bladder cancer after surgery.
Detection of ctDNA shortly after surgery may overcome clinical limitations.
Thomas Powles et al, ctDNA guiding adjuvant immunotherapy in urothelial carcinoma, Nature (2021).
Thomas Powles et al, ctDNA guiding adjuvant immunotherapy in urothelial carcinoma, Nature (2021).
The researchers evaluated the treatment results of patients (581 people) in the randomized phase III trial (IMvigor010) and phase II study (ABACUS), and analyzed whether the drug Atezolizumab can reduce the recurrence of high-risk invasive urothelial cancer
The research team found that patients who were positive for ctDNA in their blood after surgery had a higher risk of cancer recurrence than those who were negative for ctDNA
Patients who are positive for ctDNA in their blood after surgery have a higher risk of cancer recurrence than those who are negative for ctDNA
Patients with ctDNA positive have improved disease-free survival and overall survival in the atezolizumab treatment group
The adjuvant use of atezolizumab may be related to improving the prognosis of patients
ctDNA testing is more accurate than traditional radiology in identifying disease recurrence
Original source:
https:// href="https://" target="_blank" rel="noopener">https://